Glenmark Pharma shares in focus after FDA grants fast track status to cancer drug
shares will be in focus on Tuesday after the company announced that its innovation arm, Ichnos Glenmark Innovation (IGI), has received 'fast track' designation from the US Food and Drug Administration (FDA) for its investigational therapy ISB 2001.
The designation applies to adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of treatment, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
ISB 2001 is a tri-specific antibody therapeutic designed to target BCMA and CD38 on myeloma cells, as well as CD3 on T cells, enabling a targeted immune response against cancer. The therapy is currently being evaluated in a Phase 1 dose expansion clinical study.
Play Video
Pause
Skip Backward
Skip Forward
Unmute
Current Time
0:00
/
Duration
0:00
Loaded
:
0%
0:00
Stream Type
LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
1x
Playback Rate
Chapters
Chapters
Descriptions
descriptions off
, selected
Captions
captions settings
, opens captions settings dialog
captions off
, selected
Audio Track
default
, selected
Picture-in-Picture
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text
Color
White
Black
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Text Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Transparent
Caption Area Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Transparent
Semi-Transparent
Opaque
Font Size
50%
75%
100%
125%
150%
175%
200%
300%
400%
Text Edge Style
None
Raised
Depressed
Uniform
Drop shadow
Font Family
Proportional Sans-Serif
Monospace Sans-Serif
Proportional Serif
Monospace Serif
Casual
Script
Small Caps
Reset
restore all settings to the default values
Done
Close Modal Dialog
End of dialog window.
Ichnos Glenmark Innovation recently completed the dose escalation portion of its Phase 1 clinical trial in patients with heavily pre-treated multiple myeloma.
Initial results from the study, presented during an oral session at the American Society of Hematology (ASH) Annual Meeting in December 2024, demonstrated a high overall response rate (ORR), durable responses, and a favorable safety profile.
Live Events
Complete results from the dose escalation portion will be presented in a rapid oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 2, 2025.
The FDA's fast track designation is intended to facilitate the development and accelerate the review of drugs that treat serious conditions and address unmet medical needs, with the goal of making important new treatments available to patients sooner.
A drug granted fast track status may be eligible for more frequent meetings and communications with the FDA, as well as rolling review of any marketing application.
It may also qualify for priority review if certain criteria are met. Notably, ISB 2001 was previously granted 'orphan drug' designation by the FDA in July 2023.
Also Read:
8 Nifty Microcap stocks that can jump 100-230% in the next 12 months
Glenmark Pharma: Price Target
According to Trendlyne data, the average target price for the stock is Rs 1,691, indicating an upside of 20% from current levels. The consensus recommendation from 12 analysts is a 'Buy'.
Also Read:
5 timeless Warren Buffett quotes every investor should know
Glenmark Pharma: Share price performance
On Monday,
Glenmark Pharma shares
closed 2.2% higher at Rs 1,405.7 on the BSE, while the benchmark Sensex rose 0.37%. The stock has declined 13% year-to-date but has surged 155% over the past two years. Its current market capitalisation stands at Rs 39,670 crore.
Also Read:
SBI, LIC among 10 large-cap stocks that are below industry PE levels can rally up to 32%
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
10 hours ago
- Time of India
US health experts to reassess hormone replacement therapy risks
Washington: US health authorities are set Thursday to reassess Hormone Replacement Therapy (HRT), a treatment used by menopausal women around the world but long clouded by debate over its risks. HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes and vaginal discomfort. But its use has plummeted in recent years amid concerns over rare side effects, including a potential link to invasive breast cancer. Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, has long advocated for HRT, saying its risks have been overstated. "For decades, hormone replacement therapy for women -- that is estrogen or estrogen plus progesterone -- has helped women alleviate the symptoms of menopause, including hot flashes, dryness, mood swings, weight gain and poor sleep quality, to name a few," he said in a video. He added that when initiated within a decade of the onset of the transitional period before menopause, HRT may even reduce cognitive decline, the risk of Alzheimer's, and prevent osteoporosis and cardiovascular disease. Makary blamed the drop in HRT use on a landmark clinical trial, the Women's Health Initiative, which was halted in the early 2000s after it flagged increased risks of breast cancer and stroke. But he said subsequent studies had not replicated the findings on breast cancer. Critics of the trial argue it was flawed because the participants were too far from menopause, and that the formulations used are now outdated. Still, the issue remains divisive within the medical community. The FDA's own warning label for HRT -- which can be administered through various means including orally, through skin patches, or vaginally -- cites risks including endometrial cancer, breast cancer, and life-threatening blood clots. This week, the American Journal of Physicians published an editorial that found limited benefits and significant harms associated with HRT. "Menopause is a positive life experience for many women and should not be medicalized," the authors concluded. The nature of the FDA expert meeting is also unusual. Unlike standard practice before the Trump administration, no agenda was publicly posted. Several of the named panelists have ties to companies offering menopause treatments or who belong to the advocacy group "Let's Talk Menopause," which receives funding from pharmaceutical companies and campaigns to revise the FDA warning label.
Mint
14 hours ago
- Mint
Sarepta Says Another Patient Died After Receiving Gene Therapy
(Bloomberg) -- Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths of two teenage boys. A company spokesperson said a patient had died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy, which often weakens muscles around the hips and shoulders. The company told regulators and investigators about the death 'in an appropriate and timely manner,' the spokesperson said in a statement. 'While we do everything possible to ensure patient safety, there is inherent risk in clinical trials, and we are grateful to the courageous patients and families who participate,' the spokesperson said. Sarepta has faced pressure after reporting that two teenage boys had recently died of acute liver failure while being treated with Elevidys, a gene therapy approved to treat Duchenne muscular dystrophy. Both of those fatalities occurred in patients who weren't able to walk because of the muscle-wasting disease. The company said Wednesday that it had agreed to warn doctors and patients about the risk of liver failure from Elevidys at the request of the US Food and Drug Administration. On a call with analysts Wednesday, Sarepta executives said that the warning label appeared to resolve the FDA's concerns with using the gene therapy to treat children who can walk. That same day, the company said it was cutting more than a third of its workforce and pausing several drugs in its pipeline. The moves would contribute to an estimated $400 million in annual cost savings, the company said. Sarepta said Wednesday it was still in dialogue with the FDA about resolving safety concerns for the other portion of the Duchenne market, people who are no longer able to walk. More stories like this are available on
India Today
19 hours ago
- India Today
US FDA rejects GSK's blood cancer drug over safety, limited treatment benefit
The US Food and Drug Administration's (FDA) panel of independent advisers on Thursday rejected GSK's bid to reintroduce its blood cancer drug Blenrep, citing safety concerns and limited clinical benefit in treating relapsed or refractory multiple to Reuters, the drug was withdrawn from the US market in 2022 after it failed to show superiority over existing treatments in a late-stage study. However, the U.K.'s drug regulator approved Blenrep combination treatments in is an antibody-drug conjugate, a type of therapy that targets and destroys tumor cells while sparing healthy ones. GSK's US-listed shares fell nearly 6% after the panel voted 5–3 against Blenrep in combination with bortezomib and dexamethasone, stating that its benefits at the proposed dosage did not outweigh its risks. The panel also voted 7–1 against Blenrep when combined with pomalidomide and dexamethasone, reports company did not immediately respond to a request for comment. Bortezomib and pomalidomide are approved cancer therapies, while dexamethasone is a widely used generic steroid FDA panel's vote followed warnings by agency staff reviewers earlier in the week, who raised concerns about ocular toxicity, including blurred vision, photophobia, and dry eyes. Even when Blenrep was initially approved in the US, it carried a warning for eye-related side effects."It is really disappointing to see the fact that we're still allowing drugs to gain approval with less than 5% US enrollment," said panelist Dr. Daniel Spratt, associate chief scientific officer at University Hospitals Cleveland Medical Center. According to Reuters, GSK's new application relied on two late-stage trials showing that the drug combinations reduced the risk of death and slowed cancer progression.- EndsWith inputs from ReutersMust Watch
